When does Padcev (enfortumab vedotin-ejfv) patent expire?
You need the answer for a specific “Padcev patent,” because “Padcev” has multiple patents covering different things (the drug molecule, related manufacturing processes, and various formulations or methods), each with its own expiration date. Patent expiry also depends on the country and whether any extensions apply.
The information provided here does not include any Padcev patent numbers, jurisdiction(s), or expiration dates, so I can’t state a specific expiry date for Padcev from the supplied material.
What you need to know to find the right Padcev patent expiry date
Most patent-expiry lookups require:
- The jurisdiction (US, EP, UK, etc.), since expiry dates differ by country.
- The specific patent family or patent number you care about (drug substance vs. formulation vs. manufacturing vs. method-of-use).
- Whether patent term adjustments or extensions apply (in the US, for example, patent term adjustments and possible pediatric exclusivity can change the effective end date).
If you’re asking because of biosimilar/generic timing (Hatch-Waxman)
For drugs like Padcev, the time competitors can launch may be driven less by a single “compound patent expiry” and more by:
- The last-expiring relevant patent(s) listed for reference products, and
- Any regulatory exclusivities that can delay approval, even after one patent expires.
To answer your question precisely, share:
1) the country you mean (e.g., US), and
2) the patent number or a link to the listing you’re looking at (or tell me whether you mean the “drug” patent, “formulation,” or the “last listed” patent).
Then I can give the exact expiration date(s) for that specific Padcev patent context.
Sources
No sources were provided with the question, so no citations are available.